Skip to main content
An official website of the United States government
Español
Email

Cancer Currents: An NCI Cancer Research Blog

A blog featuring news and research updates from the National Cancer Institute.

An illustrated banner to represent NCI's Cancer Currents research news blog. The design features interconnected scenes: a patient receiving care, a researcher in a lab, a tumor model, a laptop and mobile device displaying research articles, fitness activity, a clinical setting, and a researcher giving a scientific presentation. The background showcases rolling hills and abstract buildings.
  • A three-dimensional image shows a zoomed-in view of a diabody connecting a T cell and a cancer cell. The diabody is depicted as a ribbon structure.
    • By Nadia Jaber

    Researchers have developed synthetic antibodies, called diabodies, that block the activity of two of the most notorious cancer-related proteins, RAS and p53. In experiments in mice, the synthetic antibodies shrank tumors with these mutated proteins.

  • Illustration showing how blinatumomab brings a T cell and cancer cell together.
    • By Edward Winstead

    The results of two trials establish blinatumomab (Blincyto) as a new standard treatment for children and young adults with high-risk relapsed B-cell acute lymphoblastic leukemia after remission has been achieved and before a stem cell transplant.

  • Illustration of kidney anatomy showing renal tubules
    • By Sharon Reynolds

    Cabozantinib (Cabometyx) is an effective initial treatment for people with metastatic papillary renal cell carcinoma (PRCC), a rare type of kidney cancer. A clinical trial showed the drug was more effective than the current standard treatment.

  • Woman with short hair sitting comfortably in a chair by a window, smiling while using a smartphone. She is wearing a pink cardigan over a denim shirt.
    • By Carmen Phillips

    Combining text messaging with mailing people free at-home FIT kits helped increase screening for colorectal cancer among a predominantly Black population, a new study has found. It’s part of a larger effort to reduce disparities in cancer screening.

  • Range of scores for the Decipher test showing low, intermediate, and high risk of prostate cancer metastasis
    • By Nadia Jaber

    For some men with prostate cancer, a genetic biomarker test called Decipher may help predict if their cancer will spread elsewhere in the body. The test could help determine whether hormone therapy, which can cause distressing side effects, is needed.

  • Emil Freireich working with a blood cell separator at MD Anderson Cancer Center.
    • By Norman E. Sharpless, M.D.

    Following the death of Dr. Emil Freireich in February, NCI Director Norman E. Sharpless reflects on the accomplishments and legacies of Dr. Freireich and several other cancer research luminaries who have passed in recent years.

  • Illustration comparing two cells: one with active estrogen receptors (left) and one lacking them (right). The left cell shows estrogen binding to receptors, leading to DNA interaction and protein production, including progesterone receptors. The right cell, without active receptors, shows no such activity.
    • By Elia Ben-Ari

    For some people with ER-positive breast cancer, a new imaging test may help guide decisions about receiving hormone therapy, according to a new study. The test can show whether estrogen receptors in tumors are active and responsive to estrogen.

  • CT machine with a tech
    • By Edward Winstead

    After a steep drop in screening for common cancers early in the COVID-19 pandemic, researchers are now exploring ways to improve cancer screening during the current crisis and beyond.

  • Breast cancer test results using the Oncotype DX® test. Recurrence Score (RS): 32, indicating a higher risk of cancer recurrence. Distant Recurrence Risk at 9 Years (with hormone therapy alone such as aromatase inhibitors or tamoxifen): 20% (with a 95% confidence interval of 15% to 27%). Group Average Chemotherapy Benefit for those with RS 26–100: greater than 15% (95% confidence interval of 9% to 37%).
    • By Nadia Jaber

    The test, which helps guide treatment decisions, was not as good at predicting the risk of death from breast cancer for Black patients as for White patients, a new study has found. The findings highlight the need for greater racial diversity in research studies.

  • Suicide Rate in People with Cancer Declining Factoid
    • By Sharon Reynolds

    Cancer-related suicides dipped each year between 1999 and 2018 in the United States, a recent study has found. Yet, people who have had cancer remain at high risk for suicide and improvements in supportive care are needed, experts say.

< Older Posts Newer Posts >
Email